GlassScriptPhysician profile
Ulker Tok
NPI 1073580924
$19,732.59
in general payments reported to CMS, 2019-2025
42 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,118 · 2020: $2,417 · 2021: $2,589 · 2022: $2,668 · 2023: $3,038 · 2024: $2,903 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,886 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,885.50 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,529.43 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $4,418.29 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $2,950.58 | 2019-2025 | |
| Ucb, INC. | $1,126.75 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $972.32 | 2019-2025 | Benlysta |
| Genzyme Corporation | $695.81 | 2019-2025 | |
| Lilly USA, LLC | $692.20 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $617.39 | 2019-2025 | Orencia |
| Organon LLC | $537.32 | 2022-2025 | Hadlima, Renflexis, Nexplanon |
| Astrazeneca Pharmaceuticals LP | $470.87 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $408.72 | 2019-2021 | |
| Celgene Corporation | $387.08 | 2019 | |
| Genentech USA, INC. | $239.19 | 2019-2021 | |
| Radius Health, INC. | $211.95 | 2019-2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $146.60 | 2022-2024 | Opsumit, Uptravi |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulker Tok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.